Foreign media: Trump announces phased imposition of tariffs on imported generic drugs into the U.S.: 0% tariff for two years starting August 1, 2026; 100% tariff from August 2028; then doubling again to 200% in 2029, aiming to force pharmaceutical companies to relocate production back to the U.S.
However, industry experts point out that rebuilding pharmaceutical manufacturing capacity in the U.S. is complex and extremely costly, with active pharmaceutical ingredients (APIs) still heavily reliant on imports; even a 200% tariff would be insufficient to alter the underlying cost structure. This policy would severely impact India — which supplies nearly 50% of U.S. generic drugs, with the U.S. accounting for about one-third of India’s pharmaceutical exports — while China dominates the upstream supply of raw materials.
An analysis suggests that the two-year window provides India with room for negotiation, but long-term risks are significant, with some low-margin products potentially exiting the market due to commercial infeasibility.
Original article: toutiao.com/article/1871403315639372/
Disclaimer: The views expressed in this article are solely those of the author.